Bizarre Patents
A small umbrella which may be removably attached to a beverage container in order to shade the beverage container from the direct rays of the sun.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120128624 | Recombinant Human Albumin-Granulocyte Macrophage Colony Stimulating Factor Fusion Protein With Long-Lasting Biological Effects Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide havin... | 05/24/2012 |
| 20120107235 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the tre... | 05/03/2012 |
| 20120107268 | LYMPH NODE-TARGETING NANOPARTICLES Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2, IL-23, IL-1α, IL-10, IL-18, and combinations thereof. Further provided are met... | 05/03/2012 |
| 20120082640 | Small molecule apoptosis promoters The invention provides small molecule mimics of the Smac peptide that are dimer- or dimer-like compounds having two amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions compri... | 04/05/2012 |
| 20120082641 | FORMULATIONS FOR BOVINE GRANULOCYTE COLONY STIMULATING FACTOR AND VARIANTS THEREOF This invention provides stable aqueous formulations comprising a bG-CSF polypeptide or a variant thereof, a buffer substance, and an excipient, wherein said formulation is substantially free of polyoxyethylene (20) sorbitan monolaurate. The invention also provides metho... | 04/05/2012 |
| 20120082642 | Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors A method for treating adult onset neurodegenerative diseases and diabetes by administering an effective dose of Granulocyte-Colony Stimulating Factors.... | 04/05/2012 |
| 20120082644 | CYTOKINES AND NEUROANTIGENS FOR TREATMENT OF IMMUNE DISORDERS The present invention provides methods of regulating an immunological disorder comprising administering to a subject an effective amount of (i) an autoimmune antigen in conjunction with (ii) an anti-inflammatory cytokine. Compositions including the same are also provide... | 04/05/2012 |
| 20120070407 | Therapy for Promoting Cell Growth There is disclosed the use of a composition for promoting neuronal growth of neurons in tissues of the central or peripheral nervous system. There is also disclosed a method for inducing proliferation or differentiation of neuronal cells.... | 03/22/2012 |
| 20120070403 | USE OF G-CSF FOR THE EXTENSION OF THE THERAPEUTIC TIME-WINDOW OF THROMBOLYTIC STROKE THERAPY The present invention relates to the use of G-CSF and derivatives thereof for extending the therapeutic window of subsequent thrombolytic treatment of acute stroke, and thereby, allowing the diagnostic examinations which are necessary prior to the thrombolytic treatment... | 03/22/2012 |
| 20120052116 | IMMUNOGENIC EPITOPES OF NGEP ANTIGEN The invention provides a peptide comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) New Gene Expressed in Prostate (NGEP), which can be used in vaccine prevention or therapy of prostate cancer, as well as a nucleic acid... | 03/01/2012 |
| 20120052043 | Chemokine-Chaperone Fusion Proteins A fusion protein comprising at least one chemokine or a derivative or fragment thereof and at least one peptide derived from a chaperone. The fusion protein can be provided in a pharmaceutical preparation for the treatment of inflammatory conditions or cancer.... | 03/01/2012 |
| 20120045487 | MULTIPHASIC MICROFIBERS FOR SPATIALLY GUIDED CELL GROWTH A multiphasic microfiber for a three-dimensional tissue scaffold and/or cellular support is provided in one aspect that includes at least one biocompatible material. The multiphasic microfiber optionally has a first phase and at least one distinct additional phase and i... | 02/23/2012 |
| 20120045411 | SHORT BETA-DEFENSIN-DERIVED PEPTIDES The invention is directed to beta-defensin-derived peptides and their use in modulating the activity of hematopoietic cells and other CXCR4-expressing cells. Specifically, the invention provides compositions and methods useful in the treatment of cancer. The invention f... | 02/23/2012 |
| 20120045412 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. ... | 02/23/2012 |
| 20120045413 | Human papilloma virus peptide-specific T-cell response for treatment of warts The inventors have treated human patients for warts by intralesional injection of Candida antigen to induce a delayed-type hypersensitivity response in the patients. This creates an immune response that recognizes the antigens of the human papilloma virus (HPV) f... | 02/23/2012 |
| 20120042613 | Long-Term Storage of Non-Glycosylated Recombinant Human G-CSF The present invention provides a method for stable long-term storage of non-glycosylated recombinant human G-CSF, wherein an aqueous acetate or glutamate buffered G-CSF composition containing non-glycosylated recombinant human G-CSF and sorbitol is cooled to a temperatu... | 02/23/2012 |
| 20120039801 | SPARC binding peptides and uses thereof Disclosed are SPARC and albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents In particular, compositions comprising SPARC binding peptide—Antibody Fc domain fusion proteins and methods of their use are dis... | 02/16/2012 |
| 20120039839 | Hypoxia Induced Mitogenic Factor We found that FIZZ1/RELMα is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELMα was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELMα protein stimulates rat pulmonary microv... | 02/16/2012 |
| 20120039797 | Antibody Therapy The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.... | 02/16/2012 |
| 20120039845 | NUCLEOSIDE PRODRUGS AND USES THEREOF Compounds having the formula I or II, wherein R1, R2, B, and V are as defined herein, are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication. 02/16/2012 | |
| 20120034184 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION The present invention relates to the use of nucleoside derivatives of formula I
| 02/09/2012 |
| 20120034185 | ANTI-CD20 ANTIBODIES AND FUSION PROTEINS THEROF AND METHODS OF USE The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies ... | 02/09/2012 |
| 20120034183 | COMPOSITIONS AND METHODS FOR GROWING EMBRYONIC STEM CELLS Compositions including topical formulations comprising secreted products obtained from the culture medium of human embryonic germ (EG) cell derivatives and particular combinations of components therefrom are provided for treatment of various dermatological conditions, s... | 02/09/2012 |
| 20120020912 | PROSTATE CANCER VACCINE Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor ... | 01/26/2012 |
| 20120020914 | LEUKEMIA INHIBITORY FACTOR (LIF) FOR USE IN REPRESSING HUMAN PAPILLOMAVIRUS (HPV) TRANSCRIPTION Embodiments of the invention are related to leukemia inhibitory factor (LIF) for use in repressing human papillomavirus (HPV) transcription. Processes and related kits are described for treating a HPV-associated papillomatous proliferation, for treating a HPV-associated... | 01/26/2012 |
| 20120020913 | METHODS FOR PANCREATIC TISSUE REGENERATION Disclosed are methods of expanding populations of pancreatic cells or inducing the generation of pancreatic progenitor cells in a subject or in culture using a therapeutically effective amount of a TWEAK receptor agonist. These methods may be used to treat diseases or c... | 01/26/2012 |
| 20120021036 | COMPOSITE NANOSTRUCTURES AND METHODS FOR MAKING AND USING THEM The invention provides nanostructures or products of manufacture for use as ex vivo or in vivo composition (e.g., a drug, or a therapeutic, diagnostic or imaging reagent) delivery vehicles. In one aspect, the invention provides nanoparticles comprising several compartme... | 01/26/2012 |
| 20120014869 | MUC18 TARGETING PEPTIDES Provided are MUC 18 targeting peptides which may be used, e.g., to therapeutically target B-I lymphocytes to reduce the influence of these cells on the metastatic potential of melanoma cells and/or to target cancerous cells, including certain melanoma and leukemia cells... | 01/19/2012 |
| 20120014879 | USE OF TUMOR NECROSIS FACTOR-alpha RECEPTOR p75 FOR TREATMENT OF ISCHEMIA-INDUCED NEOVASCULARIZATION Improvements on the basic method used for BEAMing increase sensitivity and increase the signal-to-noise ratio. The improvements have permitted the determination of intrinsic error rates of various DNA polymerases and have permitted the detection of rare and subtle mutat... | 01/19/2012 |
| 20120014910 | COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS ASSOCIATED WITH MENOPAUSE, HORMONAL VARIATIONS AND ARTHRITIS The invention provides for compositions and methods of treating or ameliorating menopausal symptoms and/or symptoms associated with hormonal variations by administering granulocyte colony-stimulating factor (G-CSF). The invention also provides for compositions and metho... | 01/19/2012 |
| 20120015037 | FUNCTIONALIZED NANOPARTICLE, METHOD FOR PREPARING THE SAME AND APPLICATION THEREOF The present invention relates to a new type of functionalized nanoparticles for drug delivery, comprising a type of polymer nanoparticles, a polymer stabilizer coating, and a drug, wherein said polymer stabilizer coating is coated on the surface of said type of polymer ... | 01/19/2012 |
| 20120009141 | FUNCTIONALIZED PYRROLIDINES AND USE THEREOF AS IAP INHIBITORS A compound of Formula 1: or a salt thereof, and methods for the use thereof, especially as an IAP inhibitor, as well as related compounds, compositions, and methods. ... | 01/12/2012 |
| 20120009144 | HETEROCYCLIC ANTIVIRAL COMPOUNDS Compounds having the formula I wherein R1, R2, R3 and X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.... | 01/12/2012 |
| 20120009140 | COMPOSTITION AND THERAPEUTIC ANTI-TUMOUR VACCINE The invention relates to a composition which induces, in a host, a cytotoxic cell response directed against cells expressing an antigen, in particular tumour cells, and which comprises red blood cells containing said antigen. These red blood cells may be in the form of ... | 01/12/2012 |
| 20120009139 | Methods and Compositions for Promoting Organ Development Compositions and methods are provided for promoting organ development in warm blooded animals, and in particular in certain aspects a premature infant or foetus. Compositions and methods are also provided for the administration of at least one colony stimulating factor-... | 01/12/2012 |
| 20120009145 | Biodegradable Cross-Linked Cationic Multi-block Copolymers for Gene Delivery and Methods of Making Thereof A biodegradable cross-linked cationic multi-block copolymer of linear polyethylenimine (LPEI) wherein the LPEI blocks are linked together by hydrophilic linkers with a biodegradable disulfide bond and methods of making thereof. The biodegradable cross-linked cationic mu... | 01/12/2012 |
| 20120009245 | Administration of Growth Factors for the Treatment of CNS Disorders A method and system that is directed to the local delivery of growth factors to the mammalian CNS to treat CNS disorders associated with neuronal death and/or dysfunction is described.... | 01/12/2012 |
| 20120009233 | Skin Care Compositions and Treatments The invention is directed compositions containing growth agents synthesized from cultured cells from skin. Skin cells such as keratinocytes and dermal fibroblasts are cultured in vitro in cell medium and in the course of culture the cultured cells synthesize and secrete... | 01/12/2012 |
| 20120003178 | EVALUATING THE THERAPEUTIC POTENTIAL OF A GLUCAN Provided herein are methods for predicting the response of a subject to administration of a glucan prior to said administration, comprising in one embodiment: isolating at least one cell from the subject, wherein the cell is capable of being stimulated by the glucan; co... | 01/05/2012 |
| 20120003179 | ANTI-CTLA-4 AND CPG-MOTIF-CONTAINING SYNTHETIC OLIGODEOXYNUCLEOTIDE COMBINATION THERAPY FOR CANCER TREATMENT The invention relates to administration of an anti-CTLA-4 antibody, particularly human antibodies to human CTLA-4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and... | 01/05/2012 |
